Who is sponsoring NCT03973021?

NCT03973021 is sponsored by Fuda Cancer Hospital, Guangzhou.

What drugs are being tested in NCT03973021?

Interventions in NCT03973021: Very small embryonic-like stem cell(VSEL).

What condition does NCT03973021 study?

NCT03973021 studies Organic Erectile Dysfunction.

Is NCT03973021 still recruiting?

NCT03973021 is currently withdrawn. Last updated 19 October 2020.

Last reviewed 2020-10-19 · How we verify

NCT03973021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Very Small Embryonic-like Stem Cells for Erectile Dysfunction

Withdrawn Phase 1, PHASE2 Last updated 19 October 2020

What this trial tests

Phase 1, PHASE2 trial testing Very small embryonic-like stem cell(VSEL) in Organic Erectile Dysfunction. Withdrawn.

Timeline

1 July 2019

Primary endpoint
20 May 2020

1 July 2020

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Start date	1 July 2019
Primary completion	20 May 2020
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

Very small embryonic-like stem cell(VSEL) — full drug profile →

Conditions studied

Organic Erectile Dysfunction — all drugs for Organic Erectile Dysfunction →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 20 to 70, male only, with Organic Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(VSELs) to organic erectile dysfunction, such as those associated with metabolic syndrome or the treatment of prostate cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03973021 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
Last refreshed: 19 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03973021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing